Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 53 pages

Showing 51 - 53


gastrointestinal cancer

ASCO 2016: Novel Antibody Significantly Improves Survival in Patients With Advanced Gastric Cancer

Findings from the European phase II FAST study showed that the novel, first-in-class antibody IMAB362 can significantly extend median survival when added to standard chemotherapy (13.2 vs 8.4 months) for patients with advanced gastric cancer. This therapy targets a protein called claudin-18 splice...

head and neck cancer
lung cancer
sarcoma
gastrointestinal cancer

AACR 2016: LOXO-101 Shows Continued Promise in Patients Whose Tumors Had NTRK Gene Fusions

The investigational drug LOXO-101, which selectively targets a family of proteins called neurotrophic tyrosine kinase receptors (NTRKs), produced significant tumor regression in patients whose tumors had NTRK gene fusions, according to data from a phase I clinical trial presented by Hong et al at...

lung cancer
gastrointestinal cancer

FDA Approves Everolimus for Neuroendocrine Tumors of Gastrointestinal or Lung Origin

The U.S. Food and Drug Administration today approved everolimus (Afinitor) for the treatment of adult patients with progressive, well-differentiated nonfunctional neuroendocrine tumors of gastrointestinal or lung origin with unresectable, locally advanced, or metastatic disease. ...

Advertisement

Advertisement



Advertisement